preview

Adverse Effect Of Isotichiin

Good Essays

Indications for use – “a reason to prescribe a medication or treatment, also known as drug indication” (Mosby’s, pg 916, 2017). High-risk neuroblastoma is an indication of use for Unituxin (dinutuximab) (FDA, 2015). Desired effects – “the ability of a drug to achieve the desired effect, also known as efficacy” (Mosby’s, pg 593, 2017). Unituxin in combination with interleukin-2 (IL-2), granulocyte-macrophage colony-stimulating factor (GM-CSF), and 13-cis-retionic acid (RA) showed that 73 percent of the participants who received this combination were alive compared to 58 percent of those receiving the oral retinoid drug, isotretinoin (RA) (FDA, 2015). Side Effects – “any reaction to or consequence of a medication or therapy” (Mosby’s, pg …show more content…

Signs or symptoms could include lumps in the abdomen, bone pain, bulging eyes, dark circles around the eyes, swollen stomach, trouble breathing, weakness or paralysis. Once neuroblastoma has been diagnosed, it has usually metastasized to the lymph nodes, bones, bone marrow, and liver (NIH, n.d.). The therapeutic classification of Unituxin (dinutuximab) is a monoclonal antibody, which is a type of immunotherapy drug. Unituxin helps the body’s immune system find and destroy cancer cells. It is used along with other treatments, which include chemotherapy, surgery, and radiation for children who have responded to previous treatment (Simon, 2015). The indications of use for Unituxin are used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of children with high-risk neuroblastoma who achieve at least a partial response to prior first-line multi-agent, multimodality therapy (United (c), 2017). The available form of Unituxin is 17.5 mg/mL (3.5 mg/mL) in a single-use vial. Children and Adolescents - 17.5 mg/m2/dose as an IV infusion over 10 to 20 hours on scheduled days for 5 cycles in combination with isotretinoin, sargramostim, and aldesleukin. On cycles 1, 3, and 5: give sargramostim 250 mcg/m2/day subcutaneously (or as an IV infusion over 2 hours) on days 1 to 14; dinutuximab on days 4, 5, 6, and 7; and isotretinoin 160 mg/m2/day PO in 2 divided doses rounded

Get Access